新医学2024，Vol.55Issue(6)：480-488,9.DOI:10.3969/j.issn.0253-9802.2024.06.012
m6A修饰在肝细胞癌药物治疗中作用研究进展
Research progress in m6A methylation modification in the treatment of hepatocellular carcinoma
摘要
Abstract
The long-term survival rate of patients with hepatocellular carcinoma(HCC)is poor,and drug efficacy is an important factor affecting clinical prognosis.N6-methyladenosine(m6A)modification is the most abundant modification in eukaryotic RNA,which can affect the occurrence and development of HCC and drug efficacy by regulating cancer-related biological functions.However,the role of m6A modification in HCC drug treatment has not been fully elucidated.Therefore,the biological functions of different regulatory members of the m6A modification process(methyltransferase,demethyltransferase and binding protein)in HCC drug treatment were illustrated,proposing that regulatory members of the m6A modification process can be used as biomarkers for HCC prognosis evaluation and have the potential to become therapeutic targets and providing novel insights for HCC precision medicine.关键词
肝细胞癌/m6A修饰/药物/系统治疗Key words
Hepatocellular carcinoma/m6A modification/Drug/Systemic treatment引用本文复制引用
冯加其,刘雄青,黄鑫昱,刘璐,王甘露..m6A修饰在肝细胞癌药物治疗中作用研究进展[J].新医学,2024,55(6):480-488,9.基金项目
深圳市科技计划项目(JCYJ20230807144059002) （JCYJ20230807144059002）
